How can hepatitis C be prevented in the long term?

International Journal of Drug Policy

Volumn 18, Issue 5, 2007, Pages 338-340

  Mateu Gelabert, Pedro ^a   Treloar, Carla ^b   Calatayud, Víctor Agulló ^c   Sandoval, Milagros ^a   Zurián, Juan Carlos Valderrama ^c   Maher, Lisa ^d   Rhodes, Tim ^e   Friedman, Samuel R ^a  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Hepatitis C prevention; Injection drug users; Qualitative research

Indexed keywords

ARTICLE; AUSTRALIA; CULTURAL FACTOR; DRUG ABUSE; DRUG DEPENDENCE; ENVIRONMENTAL FACTOR; HEALTH CARE POLICY; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MEDICAL RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SOCIAL ASPECT; STATISTICAL ANALYSIS; UNITED KINGDOM; UNITED STATES; VENEZUELA; VIRUS TRANSMISSION;

EID: 34548492492     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.06.001     Document Type: Note

References (18)

1. Aceijas C., and Rhodes T. Global estimates of HCV infection among injecting drug users. International Journal of Drug Policy 18 5 (2007) 352-358
2. Aitken C.K., Bowden S., Hellard M., and Crofts N. Indications of immune protection from hepatitis C infection. Journal of Urban Health 81 (2004) 58-60
3. Crofts N., Nigro L., Oman K., Stevenson E., and Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 92 8 (1997) 999-1005
4. Hagan H., Des Jarlais D., Stern R., Lelitiu-Weinberger C., Scheinmann R., Strauss S., et al. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal of Drug Policy 18 5 (2007) 341-351
5. Hagan H., Thiede H., and Des Jarlais D.C. HIV/hepatitis C virus co-infection in drug users: Risk behavior and prevention. AIDS 19 Suppl. 3 (2005) S199-S207
6. Hagan H., Thiede H., and Weiss N. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 91 1 (2001) 1-6
7. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., et al. Hepatitis C virus seroconversion among young injection drug users: Relationships and risks. Journal of Infectious Diseases 186 11 (2002) 1558-1564
8. Institute of Medicine of the National Academies. Preventing HIV infection among injecting drug users in high-risk countries: An assessment of the evidence (2006), The National Academies Press, Washington, DC
9. Judd A., Hickman M., Jones S., McDonald T., Parry J., Stimson G., et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London-Prospective cohort study. British Medical Journal 330 (2005) 24-25
10. Lucidarme D., Bruandet A., Ilef D., Harbonnier J., Jacob C., Decoster A., et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology of Infectious Diseases 132 4 (2004) 699-708
11. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 101 10 (2006) 1499-1508
12. Maher L., Jiong L., Jalaludin B., Chant K., and Kaldor J. High hepatitis C incidence in new injecting drug users: A policy failure?. Australian and New Zealand Journal of Public Health 31 1 (2007) 30-35
13. Marsh D., Schroeder D., Dearden K., Sternin J., and Sternin M. The power of positive deviance. BMJ 329 7475 (2004) 1177-1179
14. Miller C., Spittal P., Frankish J., Li K., Schechter M., and Wood E. Factors associated with early initiation into injection drug use among young injection drug users. 13th annual Canadian conference on HIV/AIDS research. Montreal, Canada (2004)
15. Rezza G., Sagliocca L., Zaccarelli M., Nespoli M., Siconolfi M., and Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scandinavian Journal of Infectious Diseases 28 1 (1996) 27-29
16. Thiede H., Hagan H., and Murrill S.M. Methadone treatment HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health 77 3 (2000) 331-345
17. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology 155 7 (2002) 645-653
18. World Health Organization. (2000). Hepatitis C fact sheet. Geneva. http://www.who.int/mediacentre/factsheets/fs164/en/.